API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

0

Other Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

IGL Pharma

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Q2Earth Signs Exclusive Option Agreement to License Promising Drug to Treat Bone Cancer in Children

Details:

Q2Earth has signed an Exclusive Dealing Option Agreement with IGL Pharma to potentially execute a worldwide, exclusive license agreement for the radiopharmaceutical Samarium-153 DOTMP .

Lead Product(s): Samarium Sm-153

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Q2Earth

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 22, 2020

ASK
US

Upload
your Marketing & Sales content

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Find Drugs in Development News & Deals for Samarium Sm-153

Samarium Sm-153